Japan Medical Dynamic Marketing (7600) FY2026 FY Earnings Report

Quick View

Executive Summary

For the year ended March 2026, results showed revenue of ¥239.2B (YoY -¥11.97B -4.8%), operating income of ¥5.74B (YoY -¥9.82B -63.1%), ordinary income of ¥5.34B (YoY -¥9.54B -64.1%), and net income attributable to owners of the parent of ¥2.63B (YoY -¥1.98B -77.2%), representing declines in both sales and profits. Operating margin fell to 2.4% (down 3.8pt from 6.2% prior year). Although gross margin remained high at 59.1%, SG&A expenses of ¥135.7B (56.7% of revenue) were a heavy burden, and the America segment falling into loss (operating loss ¥0.84B) pressured group profitability. At the ordinary income stage, foreign exchange gains of ¥2.31B provided support, but higher interest expense of ¥2.01B and equity-method losses of ¥0.59B depressed profit. Operating Cash Flow was ¥2.05B (YoY -80.4%), a large decline driven mainly by working capital outflow due to inventory increase of ¥15.38B, resulting in an operating CF/net income multiple of 0.78x and weak cash conversion of profit. Capex was active at ¥19.61B (8.2% of revenue), leading to negative FCF of -¥17.9B. Financing cash flow was positive ¥16.48B, funded by an increase in short-term borrowings of ¥17.44B. A year-end dividend of ¥17 was paid, but with a payout ratio of 171% and FCF in deficit, sustainability is a concern.

Drivers of Performance

[Revenue] Revenue was ¥239.2B (YoY -4.8%). By segment, Japan was ¥131.1B (YoY -3.8%) and America ¥154.1B (YoY -0.6%), both contracting. America is the core market, accounting for 54% of external-customer revenue, but demand slowdown and price competition caused revenue declines. Gross margin was high at 59.1% (down 3.2pt from 62.3% prior year), slightly lower due to product mix changes and price adjustments. R&D expense remained at ¥8.65B (3.6% of revenue), sustaining medium-term product pipeline strengthening.

[Profitability] Operating income was ¥5.74B (YoY -63.1%). SG&A was ¥135.7B (56.7% of revenue), down ¥5.23B YoY but the reduced revenue lowered fixed-cost absorption, squeezing margins; operating margin worsened to 2.4% (down 3.8pt from 6.2%). Major SG&A items were salaries and allowances ¥41.8B, selling commissions ¥35.9B, and depreciation ¥14.0B, with fixed-cost stickiness on declining sales turning operating leverage negative. Ordinary income was ¥5.34B (YoY -64.1%); non-operating items included foreign exchange gains ¥2.31B supporting profit, while interest expense ¥2.01B (up from ¥0.75B prior year, +166.8%) and equity-method losses ¥0.59B were headwinds. Extraordinary losses were minor at ¥0.41B (including impairment/disposal of fixed assets ¥0.33B), leaving profit before tax of ¥4.94B. Income taxes were ¥2.19B (effective tax rate 44.3%) and non-controlling interests ¥0.12B, resulting in net income attributable to owners of the parent of ¥2.63B (YoY -77.2%). The decline in sales and profit was driven mainly by the America segment turning to loss and the fixed-cost burden of SG&A.

Segment Analysis

The Japan segment reported revenue ¥131.1B (YoY -3.8%) and operating income ¥7.18B (YoY -9.7%), maintaining a margin of 5.5% and acting as the practical earnings driver for the group. Sales centered on orthopedic products in the domestic market, preserving a certain level of profitability. The America segment recorded revenue ¥154.1B (YoY -0.6%) and slipped into operating loss of ¥0.84B (prior-year operating income ¥5.90B), worsening margin to -0.5%. Demand slowdown and intensified price competition in the U.S. market, particularly at ODEV Co.'s manufacturing and sales operations, significantly eroded profitability. Consolidated operating income after intersegment eliminations was ¥5.74B, with America’s loss substantially offsetting Japan’s profit. Given America’s 54% share of revenue, recovery of that segment’s profitability is key to improving group margins.

Key Financial Metrics

[Profitability] ROE was 2.0% (prior year -1.8%), indicating low capital efficiency against shareholders’ equity of ¥254.0B and net income attributable to owners of the parent ¥2.63B. Net profit margin was 2.1% (based on revenue ¥239.2B and net income ¥5.12B), with operating margin 2.4% and ordinary income margin 2.2%, reflecting low profitability at each stage. Gross margin of 59.1% is high, but heavy SG&A ratio of 56.7% compresses profit. EBIT was ¥5.74B and adding depreciation ¥16.14B gives EBITDA ¥21.9B (margin 9.1%); interest coverage (EBIT/interest expense) was 2.86x, a point of caution.

[Cash Quality] Operating Cash Flow was ¥2.05B versus net income ¥5.12B, yielding operating CF/net income of 0.40x, indicating weak cash conversion. Inventory increase of ¥15.38B drove working capital outflow, leading to a sharp drop from operating CF subtotal of ¥16.34B. FCF was -¥17.9B (operating CF ¥2.05B less investing CF -¥19.95B), making the company reliant on external funding. Accrual ratio ((net income ¥5.12B - operating CF ¥2.05B)/total assets ¥356.8B) = 0.9%, low, suggesting limited one-off accounting profit.

[Investment Efficiency] Total asset turnover was 0.67x (revenue ¥239.2B / total assets ¥356.8B), indicating low asset efficiency. Capex was active at ¥19.61B (8.2% of revenue, 1.21x depreciation), aiming to enhance medium-term supply capacity and quality. Inventory was large at ¥131.0B (36.7% of total assets), with DIO (inventory / COGS × 365) at 489 days—extremely long—tying up cash.

[Financial Soundness] Equity ratio was 71.3% (net assets ¥254.3B / total assets ¥356.8B), indicating a sound capital base. Liquidity ratios are high: current ratio 323%, quick ratio 153%, but of interest-bearing debt ¥56.5B, short-term borrowings were ¥48.9B (86.5%) showing strong short-term bias. Debt/Equity was 22.2% and Debt/EBITDA 2.58x, a neutral debt level, but coverage of short-term borrowings by cash and deposits ¥31.1B is only 0.64x, indicating maturity mismatch risk. Working capital: accounts receivable ¥52.4B (DSO ~80 days), inventory ¥131.0B (DIO ~489 days), accounts payable ¥14.0B (DPO ~52 days), yielding CCC (DSO + DIO - DPO) of approx. 517 days, extremely long and necessitating urgent improvement.

Cash Flow Analysis

Operating CF was ¥2.05B (prior year ¥10.46B, -80.4%). Operating CF subtotal (profit before tax + non-cash items) secured ¥16.34B, but changes in working capital—inventory increase ¥15.38B—could not be fully offset by decreases in accounts receivable ¥9.13B and increases in accounts payable ¥0.54B, substantially reducing cash generation. Corporate tax payments were minor at ¥0.06B; interest and dividend receipts ¥0.03B and interest payments ¥2.01B were considered, leaving operating CF at ¥2.05B. Investing CF was -¥19.95B, mainly capex ¥19.61B (tangible fixed assets acquired), equivalent to 8.2% of revenue and 1.21x depreciation, signaling continued aggressive investment. Intangible asset acquisition was limited at ¥0.37B. FCF was operating CF ¥2.05B + investing CF -¥19.95B = -¥17.9B, making self-funding difficult. Financing CF was positive ¥16.48B, procured via increases in short-term borrowings ¥12.50B and long-term borrowings ¥12.16B, with repayments of long-term borrowings ¥3.90B and dividend payments ¥3.97B. Cash and deposits decreased slightly from ¥31.8B at the beginning of the period to ¥31.1B at period-end, a ¥0.75B decline; considering foreign exchange effects of ¥0.66B, external funding effectively covered FCF deficit and dividends. OCF/EBITDA ratio was 0.09x (operating CF ¥2.05B / EBITDA ¥21.9B), extremely low, indicating profit is not being converted into cash. Short-term recovery of OCF hinges on inventory reduction and improving receivables turnover to shorten CCC (currently ~517 days).

Quality of Earnings

Recurring earnings show a notable deterioration in core business, with operating margin at 2.4% sharply down from 6.2% prior year. Non-operating foreign exchange gains ¥2.31B boosted ordinary income but are largely temporary and exchange-rate dependent, lacking sustainability. FX impact accounted for about 40% of operating income ¥5.74B, highlighting weaker core profitability. Increased interest expense ¥2.01B (from ¥0.75B, +166.8%) reflects growth in short-term borrowings and rising interest burden. Equity-method loss ¥0.59B also reduced ordinary income, reflecting affiliated companies’ weak performance. Extraordinary losses were minor at ¥0.41B (including fixed asset disposal ¥0.33B), having limited effect on net income. With profit before tax ¥4.94B and corporate taxes ¥2.19B, the effective tax rate was 44.3%, high; deferred tax assets ¥14.37B accumulated suggest potential future tax relief but realization is uncertain amid weaker earnings. Accrual quality is weak: operating CF/net income 0.40x (based on net income ¥5.12B) and OCF/EBITDA 0.09x, with inventory buildup degrading earnings quality. Comprehensive income was ¥10.86B (¥10.81B attributable to owners of the parent), far exceeding net income ¥2.63B, driven mainly by ¥8.21B in foreign currency translation adjustments—paper gains from converting overseas subsidiaries’ assets/liabilities, with limited realizability. The gap between ordinary income and net income (ordinary ¥5.34B → net ¥2.63B) stems from high taxes and non-controlling interests ¥0.12B, and the high effective tax rate increases volatility in net profit. Overall, reliance on FX gains and high tax rates results in low quality of recurring, stable earnings.

Forecasts & Guidance

The company’s guidance forecasts revenue ¥253.7B (YoY +6.1%), operating income ¥4.3B (YoY -25.1%), ordinary income ¥1.4B (YoY -73.8%), net income attributable to owners of the parent ¥0.6B, EPS ¥2.28, and dividend ¥0. Compared to actuals, revenue is expected to rise, but operating income is guided down from actual ¥5.74B to ¥4.3B, indicating conservative guidance. The large expected decline in ordinary income likely incorporates a reduction in FX gains and increased interest burden. A dividend forecast of ¥0 signals priority on FCF deficit reduction and working capital improvement. Revenue growth assumes shipment of accumulated inventory and demand recovery (+6.1%), but operating income is expected to fall due to SG&A fixed-cost burden and the phasing out of FX contributions. Key KPIs for progress include America segment returning to profit, inventory compression, and lengthening of short-term borrowings; these are critical for achieving or beating guidance. Progress rates are not calculated because the fiscal year has closed; quarterly disclosures next fiscal year should be monitored for inventory levels and America segment profit trends.

Shareholder Returns

A year-end dividend of ¥17 was paid, totaling approximately ¥3.97B. Against net income attributable to owners of the parent ¥2.63B, the payout ratio was 151% (dividends ¥3.97B / net income ¥2.63B), far exceeding net income. Even on a consolidated net income basis of ¥5.12B, the payout ratio was high at 77.5%. With FCF at -¥17.9B, dividend FCF coverage was -0.22x (FCF -¥17.9B / dividends ¥3.97B), making internal funding impossible. In practice, financing CF included short-term borrowings ¥12.50B and long-term borrowings ¥12.16B, meaning dividends were effectively funded by external financing. Share buybacks were ¥0.00B (treasury stock purchases in CF statement), so total return ratio is roughly equal to the payout ratio. Next fiscal year’s guidance assumes no dividend, indicating a shift to cash preservation and prioritizing working capital improvement and debt refinancing. From a dividend sustainability perspective, cash and deposits ¥31.1B versus short-term borrowings ¥48.9B mean limited liquidity on hand; normalization of operating CF and inventory reduction to improve FCF are prerequisites for resuming dividends.

Risk Factors

1. Excessive and stagnant inventory: Inventory ¥131.0B (36.7% of total assets) with DIO 489 days is extremely long, raising high risk of markdowns or impairments from demand shortfalls or product obsolescence. Most inventory is finished goods ¥131.0B; shipment delays or intensified market competition could impair asset value. Deterioration in working capital efficiency reduces cash generation, and CCC of 517 days increases liquidity risk.

2. Deterioration in America segment profitability: America, accounting for 54% of revenue, fell into an operating loss of ¥0.84B, significantly depressing group margins. U.S. market demand slowdown and price competition lowered fixed-cost absorption at ODEV Co.’s manufacturing and sales operations. If this segment’s return to profit is delayed, consolidated operating margin (2.4%) could worsen further, making recovery of ROE and capital efficiency difficult.

3. Short-term debt concentration and interest-rate risk: Of interest-bearing debt ¥56.5B, short-term borrowings ¥48.9B (86.5%) are concentrated and cannot be covered by cash and deposits ¥31.1B (coverage 0.64x). Interest coverage is 2.86x, a cautionary level; in a rising-rate environment, interest expense will increase and further press on ordinary income. If refinancing risk and rising interest burdens materialize simultaneously, financial flexibility will deteriorate.

Industry Benchmark (Reference — Company Compilation)

Profitability & Returns

Profitability is well below the industry median, ranking in the lower tier for both operating and net margins. High SG&A fixed-cost burden and the America segment’s loss are primary causes.

Growth & Capital Efficiency

Revenue growth rate trails the industry median by 8.5pt, indicating a downturn. Demand slowdown and price competition underlie underperformance in industry-relative growth.

※ Source: Company compilation

Earnings Highlights / Items to Watch

1. Inventory remediation and returning the America segment to profitability are the highest short-term priorities. If DIO of 489 days and CCC of 517 days can be compressed, operating CF recovery and ROE improvement would follow. Reducing inventory from ¥131.0B to an appropriate level (target 120 days ≈ ¥43B) could free approx. ¥88B in cash, aiding repayment of short-term borrowings and easing interest burden. If America turns from operating loss ¥0.84B to profit, consolidated operating margin recovery above 5% is conceivable.

2. Guidance is conservative—revenue +6.1% and operating income ¥4.3B—but upside exists if inventory reduction and price/product-mix improvements materialize. FX sensitivity (about 40% of operating income) is high; continued yen weakness could re-expose non-operating benefits, while yen appreciation presents downside risk to ordinary income. Dividend guidance of ¥0 indicates a cash-conservation stance, prioritizing working capital improvement and lengthening debt maturity. Medium-term, capex ¥19.61B (8.2% of revenue) could monetize into capacity and quality improvements to support growth, but near-term priority is normalizing working capital.

---

This report is an earnings analysis document automatically generated by AI analyzing XBRL financial statement data. It does not constitute a recommendation to invest in any specific security. Industry benchmarks are reference information compiled by the company based on public financial statements. Investment decisions are your own responsibility; consult a professional advisor as needed.